Evolving your biobank business model

Webinar overview

“Biobanks have played a key role in the fight against Covid-19 by allowing researchers to access the samples they needed to study the disease and develop vaccines and treatments. While the pandemic presented a big challenge to the often-underfunded biobanks, it also provided an opportunity for growth in many other areas of research going forward.” (Carlos de Rojas, July 12, 2021, The Hidden Role of Biobanks in Covid-19 Research)

In achieving research growth, today’s Biobanks face ever increasing challenges in the form of more precise and consistent quality control, the need for training and streamlining of operations to produce that quality control, and the need for new revenue streams to support these enhanced operations. With Bruker's high-performance scientific instruments* and high-value analytical solutions, we are enabling Biobanks to breakthrough these barriers with a novel application that augments sample quality/validation, streamlines QC operations via automation, and provides a new Biobank revenue stream.


Dr. Alexander M. Funk

Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Dresden

Alexander Funk is a chemist. He has worked with a range of different techniques in magnetic resonance. Ranging from paramagnetism over imaging to metabolomics. In Dresden, he runs the Magnetic Resonance Facility including NMR Metabolomics and preclinical Imaging as well as the liquid Biobank.

Ph.D. Pedro Lopes

Field Application Scientist, Bruker BioSpin GmbH, Ettlingen

bio : Pedro Lopes holds a doctoral degree in Biophysics with experience in X-Ray Crystallography and High Resolution NMR of Proteins. As a Researcher, he applied High Pressure NMR to Proteins for discovering rare conformational states and new binding sites for interaction with small drugs. He joined Bruker in 2022 where he works as a Field Application Specialist for new solutions in the Applied, Industrial and Clinical Markets 

Key learning topics

  •  Increasing confidence in sample relevance via quality control.
  • Understanding NMR* QC parameters and their meaning.
  • Fully characterizing samples according to ISBER SPREC, focusing on pre and post-centrifugation delay characterization.

Please join us for a 60 min webinar to discuss these topics with Dr. Alexander M. Funk, Director of the Liquid Biobank and Magnetic Resonance Facility, Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Dresden and Dr. Eduardo Nascimento, Bruker BioSpin Clinical Research Applications

Who should attend

Biobank Managers and Associated Principal Investigators interested in improving sample integrity, and by extension, study integrity of clinical trials and ongoing research.

*Bruker NMR Instruments are for Research Use Only and not for Use in Clinical Diagnostic Procedures

Other Webinars from Bruker BioSpin - NMR, EPR and Imaging

Life Science Webinars by Subject Matter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.